Newsletter | September 23, 2025

09.23.25 -- STREAM Edition: Engineering Off-The-Shelf Cell Therapies For Cancer And Autoimmune Disease

Addressing Core Requirements In CGT Manufacturing Optimization

Video | Ori Biotech

Discover how a fully automated, standardized approach can enhance biological performance, reduce process timelines, and enable commercial-scale production for cell and gene therapy treatments.

Increased Productivity At Commercial Scale

Video | Cytiva

A platform that boosts CAR T therapy manufacturing with advanced automation and modular design reduces labor, increases scalability, and enhances productivity for efficient commercial-scale production.

Freezing Studies For Single-Use Solutions

Video | Charter Medical

Are you curious about how single-use solutions used in the manufacture of advanced therapies perform in ultra-low temperatures? Learn about the four common types of cryogenic studies for advanced therapies.

Pioneering Solutions That Turn Hope Into Reality

Webinar | Andelyn Biosciences

The number of AAV-mediated therapies in clinical trials continues to rise, increasing demand for doses. A scalable platform is crucial to ensure a seamless transfer from pre-clinical to commercial.

A Compact Bioreactor Designed For Smaller Working Volumes

Video | PBS Biotech, Inc.

Take a closer look at the PBS Mini, a compact bioreactor designed for 60-100mL and 300-500mL. This innovative system offers exceptional mixing capabilities while minimizing shear forces.

Scalable Suspension LVV Production Platforms

Webinar | Lonza

Review a scalable suspension-based Lenti production platform using a proprietary HEK293T clonal cell line and improvement steps to generate commercially viable therapies from concept to patient.

Engineering Off-The-Shelf Cell Therapies For Cancer And Autoimmune Disease With Ernexa Therapeutics' Sanjeev Luther

Video | Cell & Gene

On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Ernexa Therapeutics' President and CEO, Sanjeev Luther, about how the company is advancing cell therapy innovation for cancer and autoimmune disease through engineered induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs).